The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. The collaboration leverages Evotec’s hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities together with LEO Pharma’s track record of drug development and advancing science in dermatology. 

 

Evotec’s integrated discovery scientists will work in a joint team with scientists from LEO Pharma. The alliance will receive further support with high-value drug development and discovery ADME-Tox services.  

 

“We are delighted to partner with LEO Pharma on this exciting project, which leverages our industry-leading hit generation platform,” said Mario Polywka, chief operating officer, Evotec. “Working together, we are convinced we will find innovative therapeutic approaches to dermatological conditions with a high unmet medical need.”  

 

Thorsten Thormann, vice president, research, LEO Pharma, said, “Innovation through partnerships plays a key role in LEO Pharma’s approach to developing new medicines. We are confident that our alliance with Evotec will further strengthen our research and help us expedite the discovery of novel small molecule therapeutics for skin diseases, for which there are large unmet medical needs, thus helping even more patients in the future.”  

 

No financial details of this fee-for-service collaboration were disclosed.